Screener
Arcus Biosciences RCUS Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Arcus Biosciences’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001724521-26-000044
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock ($— and $14 from a related party) | — | 142 |
| Proceeds from debt issuances, net | — | 49 |
| Proceeds from issuance of common stock pursuant to equity award plans | 19 | 3 |
| Net cash provided by financing activities | 19 | 194 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | (72) | 98 |
| Cash, cash equivalents and restricted cash at beginning of period | 225 | 153 |
| Cash, cash equivalents and restricted cash at end of period | $153 | $251 |
Item 1. Financial Statements
FAQ
- What is Arcus Biosciences's financing cash flow?
- Arcus Biosciences (RCUS) reported financing cash flow of $16M in Q2 2026.
- How has Arcus Biosciences's financing cash flow changed year-over-year?
- Arcus Biosciences's financing cash flow decreased by 69.2% year-over-year, from $52M to $16M.
- What is the long-term trend for Arcus Biosciences's financing cash flow?
- Over 4 years (2021 to 2025), Arcus Biosciences's financing cash flow has grown at a 19.8% compound annual growth rate (CAGR), from $237M to $488M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Arcus Biosciences's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude